For cancer patients around the world, China and the United States pharmaceutical companies to cooperate in the promotion of drugs.

Pharmaceutical Network August 20, for global cancer patients, China and the United States well-known pharmaceutical companies will expand the PD-1 monoclonal antibody immuno-tumor drug Dabershu (Sudili monoanti injection) global strategic cooperation.
" Dabershu successfully entered the national health insurance catalog, making Itinda Bio's mission to 'develop high-quality biopharmaceuticals that ordinary people can afford' a reality.
's success in the Chinese market, we are pleased to expand our strategic partnership with Lilly Pharmaceuticals to expand Our partnership to the world.
," said Zhai Dechao, founder, chairman and president of Xinda Biopharmaceutical Group.
18th, Xinda Biopharmaceutical Group and Lilly Pharmaceutical Group of the United States jointly announced the relevant news of global strategic cooperation.
under the partnership agreement, Syntech granted Dharma's exclusive license outside China to Lilly Pharmaceuticals, which is bringing the drug to North America, Europe and beyond.
has accumulated more than $1 billion for this cooperation.
both parties reserve the right to develop products from Daberschu and other partners in their respective pipelines. according to
, Dabershu is an innovative drug jointly developed by Xinda Bio and Lilly Pharmaceuticals, which was approved in China in December 2018 to treat recurrent/incurable classic Hodgkin's lymphoma, which was published in the authoritative medical journal Lancet Hematology.
November 2019, Dabershu entered the National Health Insurance Directory.
"We believe Thatberschu will benefit more patients around the world."
this collaboration is also a good start for Dabershu and Syntech to move to the world pharmaceutical stage.
," he said.
reporter learned that Xinda Bio has set up a poverty alleviation fund to provide free Dabshu to patients with family difficulties.
, the research and development team is working to expand the scope of Dabershu's adaptations.
, Synthesa Bio and Roche Pharmaceuticals reached a partnership of more than $2 billion in the field of double-resistant and immunocellular therapy.
also established international cooperation with organizations such as the MD Anderson Cancer Center at the University of Texas.
(Complete)